SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
141.60    -24.20 (-14.60%)
Bid:
140.20
Ask:
144.80
Spread: 4.60 (3.281%)
Market Cap: £241.94m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Trading Update

3 Jul 2018 07:00

RNS Number : 3460T
McBride PLC
03 July 2018
 

3 July 2018

 

McBride plc

 

Trading Update

 

McBride plc, the leading European manufacturer and supplier of Co-manufactured and Private Label products for the Household and Personal Care market, provides the following trading update for the twelve months ending 30 June 2018.

 

Following weaker than expected sales levels in May and June 2018, the Group now expects full year adjusted Profit Before Tax to be marginally below the lower end of analyst expectations. Second half revenues for the Household segment on a like for like basis are showing growth of 3.8%. Total Household revenues in the second half, including Danlind, are expected to be 15.8% higher than the same period of last financial year.

 

In the period since the Group's Half Year results announcement in February, Household revenues in the French market have continued to show declines year on year but this has been balanced by better than expected revenues in Germany and from Danlind, such that the Group had been trading in line with its overall internal expectations. However, the Group saw weaker than expected sales levels in certain markets in May, and whilst June saw an improvement, performance across the two months means that adjusted Profit Before Tax will be marginally below the lower end of analyst expectations.

 

Input costs overall have remained stable in the period since January, however the impact from increasing volumes in the final quarter have temporarily added to the Group's operating costs, primarily from higher distribution and warehousing costs and some short term inefficiencies at certain factories.

 

Meanwhile, our Personal Care & Aerosols (PCA) business will deliver losses marginally higher than expected levels, mainly due to revenue weakness. The Group continues to implement the transformation plan for PCA at pace and in May announced proposals to close the UK Aerosols operations at Hull. Collective Consultation with the affected employees has recently been completed, with closure now expected in Spring 2019. As a result of this closure and the absorption of certain volumes into our French aerosols operations the Group expects the aerosols activities to be trading at breakeven levels from July 2019. Additionally, the Group has today announced, under a separate statement, that it has agreed terms for the sale of the European Personal Care liquids business for £12.5m with completion of the transaction expected in the last calendar quarter of 2018

 

The Group will publish its preliminary results for the 12 months to 30 June 2018 on 6th September 2018.

 

 

For further information please contact:

 

McBride plc

Rik De Vos, Chief Executive Officer

0161 203 7570

Chris Smith, Chief Financial Officer

0161 203 7570

FTI Consulting

020 3727 1017

Ed Bridges, Nick Hasell

 

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation which came into effect on 3 July 2016.

 

-Ends-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTLLLLBVDFBBBZ
Date   Source Headline
12th Jun 20267:00 amRNSTrading and Acquisition Update
11th Jun 20261:44 pmRNSDirector/PDMR Shareholding
2nd Jun 20267:00 amRNSTransaction in Own Shares
27th May 20267:00 amRNSTransaction in Own Shares
19th May 20267:00 amRNSTransaction in Own Shares
12th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSTransaction in Own Shares
1st May 20267:00 amRNSSecond tranche of share buyback programme
1st May 20267:00 amRNSTransaction in Own Shares
29th Apr 20267:00 amRNSTransaction in Own Shares
28th Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20267:00 amRNSTransaction in Own Shares
16th Apr 20267:00 amRNSTransaction in Own Shares
15th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSProposed Acquisition & Trading Conditions Update
1st Apr 20267:00 amRNSTransaction in Own Shares
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSDirector Appointment
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20266:28 pmRNSDirectorate change
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:05 amRNSInterim results for 6M ended 31 December 2025

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.